Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-eb7d3517ce728a017d7b2f838a6f78c4"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-eb7d3517ce728a017d7b2f838a6f78c4"/>
<resource>
<Composition>
<id value="composition-en-eb7d3517ce728a017d7b2f838a6f78c4"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-eb7d3517ce728a017d7b2f838a6f78c4"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-eb7d3517ce728a017d7b2f838a6f78c4</b></p><a name="composition-en-eb7d3517ce728a017d7b2f838a6f78c4"> </a><a name="hccomposition-en-eb7d3517ce728a017d7b2f838a6f78c4"> </a><a name="composition-en-eb7d3517ce728a017d7b2f838a6f78c4-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/396/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - pergoveris</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/396/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpeb7d3517ce728a017d7b2f838a6f78c4"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - pergoveris"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Pergoveris is and what it is used for</li><li>What you need to know before you use Pergoveris</li><li>How to use Pergoveris</li><li>Possible side effects</li><li>How to store Pergoveris</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What pergoveris is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What pergoveris is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Pergoveris is Pergoveris contains two different active substances called follitropin alfa and lutropin alfa . Both belong to the family of hormones called gonadotropins , which are involved in reproduction and fertility.</p><p>What Pergoveris is used for This medicine is used to stimulate the development of follicles (each containing an egg) in your ovaries. This is to help you get pregnant. It is for use in adult women (18 years old or above) who have low levels (severe deficiency) of follicle stimulating hormone (FSH) and luteinising hormone<br/>(LH). These women are usually infertile.</p><p>How Pergoveris works The active substances in Pergoveris are copies of the natural hormones FSH and LH. In your body:</p><ul><li>FSH stimulates the production of eggs</li><li>LH stimulates the release of the eggs.</li></ul><p>By replacing the missing hormones, Pergoveris allows women with low levels of FSH and LH to develop a follicle. This will then release an egg, after an injection of the hormone human chorionic gonadotropin (hCG) . This helps the women to become pregnant.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take pergoveris"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take pergoveris"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You and your partner's fertility should be evaluated before the treatment is started by a doctor experienced in treating fertility problems.</p><p>Do not use Pergoveris</p><ul><li><p>if you are allergic to follicle stimulating hormone (FSH), luteinising hormone (LH) or any of the other ingredients of this medicine (listed in section 6)</p></li><li><p>if you have a brain tumour (in your hypothalamus or pituitary gland)</p></li><li><p>if you have large ovaries or sacs of fluid within your ovaries (ovarian cysts) of unknown origin</p></li><li><p>if you have unexplained vaginal bleeding</p></li><li><p>if you have cancer in your ovaries, womb or breasts</p></li><li><p>if you have a condition that would make a normal pregnancy impossible, such as an early menopause, malformed sex organs or benign tumours of the womb.</p></li></ul><p>Do not use this medicine if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before using this medicine.</p><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before using Pergoveris.</p><p>Porphyria Talk to your doctor before you start your treatment.If you or any member of your family have porphyria (an inability to breakdown porphyrins that may be passed on from parents to children).</p><p>Tell your doctor straight away if:</p><ul><li>your skin becomes fragile and easily blistered, especially skin that has been frequently exposed to sunlight</li><li>you have stomach, arm or leg pain.</li></ul><p>In case of above events your doctor may recommend that you stop treatment.</p><p>Ovarian hyperstimulation syndrome (OHSS) This medicine stimulates your ovaries. This increases your risk of developing ovarian hyperstimulation syndrome (OHSS). This is when your follicles develop too much and become large cysts. If you get lower abdominal pain, gain any weight rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight away. They might ask you to stop using this medicine (see in section 4. under Most serious side effects ).</p><p>In case you are not ovulating and if the recommended dose and schedule of administration are adhered to, the occurrence of severe OHSS is less likely. Pergoveris treatment seldom causes severe OHSS. This becomes more likely if the medicine that is used for final follicular maturation (containing human chorionic gonadotropin, hCG) is administered (see in section 3. under How much to use for details). If you are developing OHSS your doctor may not give you any hCG in this treatment cycle and you may be told not to have sex or that you should use a barrier contraceptive method for at least four days.</p><p>Your doctor will ensure, careful monitoring of the ovarian response, based on ultrasound and blood tests (oestradiol measurements) before and during the course of treatment.</p><p>Multiple pregnancy When using Pergoveris, you have a higher risk of being pregnant with more than one child at the same time ( multiple pregnancy , mostly twins), than if you conceived naturally. Multiple pregnancy may lead to medical complications for you and your babies. You can reduce the risk of multiple pregnancy by using the right dose of Pergoveris at the right times.</p><p>To minimise the risk of multiple pregnancy, ultrasound scans as well as blood tests are recommended.</p><p>Miscarriage When undergoing stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman.</p><p>Ectopic pregnancy Women who have ever had blocked or damaged fallopian tubes (tubal disease) are at risk of pregnancy where the embryo is implanted outside the womb (ectopic pregnancy). This is whether the pregnancy is obtained by spontaneous conception or with fertility treatments.</p><p>Blood clotting problems (thromboembolic events) Talk to your doctor before using Pergoveris if you or a member of your family have ever had blood clots in the leg or in the lung, or a heart attack or stroke. You may be at a higher risk of serious blood clots or existing clots might become worse with Pergoveris treatment.</p><p>Tumours of sex organs There have been reports of tumours in the ovaries and other sex organs, both benign and malignant, in women who have undergone multiple regimens for infertility treatment.</p><p>Allergic reactions There have been isolated reports of non-serious allergic reactions to Pergoveris. If you have ever had this type of reaction to a similar medicine, talk to your doctor before using Pergoveris.</p><p>Children and adolescents Pergoveris is not for use in children and adolescents below 18 years old.</p><p>Other medicines and Pergoveris Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>Do not use Pergoveris with other medicines in the same injection, except for follitropin alfa, if prescribed by your doctor.</p><p>Pregnancy and breast-feeding Do not use Pergoveris if you are pregnant or breast-feeding.</p><p>Driving and using machines It is not expected that this medicine will affect your ability to drive or use machines.</p><p>Pergoveris contains sodium Pergoveris contains less than 1 mmol sodium (23 mg) per dose that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take pergoveris"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take pergoveris"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Using this medicine</p><ul><li>Pergoveris is intended to be given by injection just under the skin (subcutaneously). To minimise skin irritation, select a different injection site each day.</li><li>It comes as a powder and liquid, which you need to mix together and then use straight away.</li><li>Your doctor or nurse will show you how to prepare and inject this medicine. They will supervise your first injection.</li><li>If they are satisfied that you can administer Pergoveris safely, you can then prepare and inject the medicine yourself at home. When you do this, please carefully read and follow the instructions hereafter called How to prepare and use the Pergoveris powder and solvent .</li></ul><p>How much to use The usual starting dose is one vial of Pergoveris every day.</p><ul><li>According to your response, your doctor may decide to add every day a dose of a licensed follitropin alfa preparation to your Pergoveris injection. In this case, the follitropin alfa dose is usually increased every 7 or every 14 days by 37.5 to 75 IU.</li><li>Treatment is continued until you get the desired response. This is when you have developed a suitable follicle, as assessed using ultrasound scans and blood tests.</li><li>This may take up to 5 weeks.</li></ul><p>When you get the desired response, you will be given a single injection of human chorionic gonadotropin (hCG) 24 to 48 hours after your last Pergoveris injection. The best time to have sex is on the day of the hCG injection and the day after. Alternatively, intrauterine insemination or another medically assisted reproduction procedure may be performed based on your doctor s judgment.</p><p>If your body responds too strongly, your treatment will be stopped and you will not be given any hCG (see in section 2. under Ovarian hyperstimulation syndrome (OHSS) ). In this case, your doctor will give you a lower follitropin alfa dose in the following cycle.</p><p>How to prepare and use the Pergoveris powder and solvent Before starting the preparation, please read these instructions the whole way through first: Give yourself the injection at the same time each day.</p><ol type="1"><li>Wash your hands and find a clean area</li></ol><ul><li>It is important that your hands and the items you use be as clean as possible</li><li>A good place is a clean table or kitchen surface</li></ul><ol start="2" type="1"><li>Get together everything you need and lay them out</li></ol><ul><li>1 vial containing Pergoveris powder</li><li>1 vial containing water for injections (solvent)</li></ul><p>Not provided in the pack:</p><ul><li>2 alcohol swabs</li><li>1 empty syringe for injection</li><li>1 needle for preparation</li><li>1 fine bore needle for injection under the skin</li><li>one sharps container for safe disposal of glass and needles</li></ul><ol start="3" type="1"><li>Preparing the solution</li></ol><ul><li><p>Remove the protective cap from the vial filled with water (solvent vial).</p></li><li><p>Attach the needle for preparation to the empty syringe for injection.</p></li><li><p>Draw up some air into the syringe by pulling the plunger to approximately the 1 mL mark.</p></li><li><p>Insert the needle into the vial, push the plunger to expel the air.</p></li><li><p>Turn the vial upside down and gently draw up all the water (solvent).</p></li><li><p>Remove the syringe from the vial and set it down carefully. Do not touch the needle and do not allow the needle to touch any surface.</p></li><li><p>Remove the protective cap from the vial filled with Pergoveris powder.</p></li><li><p>Pick up your syringe and slowly inject the contents of the syringe into the vial of powder.</p></li><li><p>Swirl gently without removing the syringe. Do not shake.</p></li><li><p>After the powder has dissolved (which usually occurs immediately), check that the resulting solution is clear and does not contain any particles.</p></li><li><p>Turn the vial upside down, gently draw the solution back into the syringe. Check for particles as before, and do not use if the solution is not clear.</p></li></ul><ol start="4" type="1"><li>Getting the syringe ready for injection</li></ol><ul><li>Change the needle for the fine bore needle.</li><li>Remove any air bubbles: If you see air bubbles in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top. Push the plunger until the air bubbles are gone.</li></ul><ol start="5" type="1"><li>Injecting the dose</li></ol><ul><li>Immediately inject the solution. Your doctor or nurse will have already advised you where to inject (e.g. tummy, front of thigh). To minimise skin irritation, select a different injection site each day.</li><li>Clean the chosen skin area with an alcohol swab using a circular motion.</li><li>Firmly pinch the skin together and insert the needle at a 45 to 90 angle using a dart-like motion.</li><li>Inject under the skin, as you were taught. Do not inject directly into a vein.</li><li>Inject the solution by pushing gently on the plunger. Take as much time as you need to inject all the solution.</li><li>Then withdraw the needle and clean the skin with a new alcohol swab using a circular motion.</li></ul><ol start="6" type="1"><li>After the injection</li></ol><p>Dispose of all used items. Once you have finished your injection, immediately discard all needles and empty vials in your sharps container. Any unused solution must be discarded.</p><p>If you use more Pergoveris than you should The effects of an overdose of Pergoveris are unknown, nevertheless one could expect OHSS to occur. However this will only occur if hCG is administered (see in section 2. under Ovarian hyperstimulation syndrome (OHSS) ).</p><p>If you forget to use Pergoveris Do not use a double dose to make up for a forgotten dose. Please contact your doctor.</p><p>If you have any further question on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Most serious side effects Contact your doctor straight away if you notice any of the below listed side effects. The doctor might ask you to stop using Pergoveris.</p><p>Allergic reactions Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty breathing can sometimes be serious. This side effect is very rare.</p><p>Ovarian hyperstimulation syndrome (OHSS)</p><ul><li>Lower abdominal pain together with nausea or vomiting. These may be the symptoms of ovarian hyperstimulation syndrome (OHSS). Your ovaries may have over-reacted to the treatment and formed large sacs of fluid or cysts (see in section 2. under Ovarian hyperstimulation syndrome (OHSS) ). This side effect is common. If this happens, your doctor will need to examine you as soon as possible.</li><li>The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest. This side effect is uncommon (may affect up to 1 in 100 people).</li><li>Complications of OHSS such as twisting of ovaries or blood clotting occur rarely (may affect up to 1 in 1 000 people).</li><li>Serious blood clotting problems (thromboembolic events) usually with severe OHSS are found very rarely. This could cause chest pain, breathlessness, stroke or heart attack. In rare cases this can also happen independently of OHSS (see in section 2. under Blood clotting problems (thromboembolic events) ).</li></ul><p>Other side effects</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>sacs of fluid within the ovaries (ovarian cysts)</li><li>headache</li><li>local reactions at the injection site such as pain, itching, bruising, swelling or irritation.</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>diarrhoea</li><li>breast pain</li><li>feeling sick or vomiting</li><li>abdominal or pelvic pain</li><li>abdominal cramp or bloating.</li></ul><p>Very rare (may affect up to 1 in 10 000 people):</p><ul><li>Your asthma may get worse.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store pergoveris"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store pergoveris"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the vials and the carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 25 C. Store in the original package in order to protect from light.</p><p>The medicine must be administered immediately after reconstitution.</p><p>Do not use Pergoveris if you notice any visible signs of deterioration.</p><p>The reconstituted solution should not be administered if it contains particles or is not clear.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Pergoveris contains The active substances are follitropin alfa and lutropin alfa.</p><ul><li>One vial contains 150 IU (equivalent to 11 micrograms) of follitropin alfa and 75 IU (equivalent to 3 micrograms) of lutropin alfa.</li><li>After reconstitution, each mL of the solution contains 150 IU follitropin alfa and 75 IU lutropin alfa per milliliter.</li></ul><p>The other ingredients are</p><ul><li>Sucrose, disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate, methionine, polysorbate 20, as well as concentrated phosphoric acid and sodium hydroxide for pH-adjustment.</li></ul><p>What Pergoveris looks like and contents of the pack</p><ul><li>Pergoveris is presented as a powder and solvent for solution for injection.</li><li>The powder is a white to off-white lyophilised pellet in a glass vial with a bromobutyl rubber stopper containing 150 IU (equivalent to 11 micrograms) of follitropin alfa and 75 IU (equivalent to 3 micrograms) of lutropin alfa.</li><li>The solvent is a clear colourless liquid in a glass vial containing1 mL of water for injections.</li><li>Pergoveris is supplied in packs of 1, 3 and 10 vials of powder with the corresponding number of solvent s vials (1, 3 and 10 vials). Not all pack sizes may be marketed.</li></ul><p>Marketing Authorisation Holder Merck Europe B.V., Gustav Mahlerplein 102, 1082 MA Amsterdam, The Netherlands</p><p>Manufacturer Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), 70026 Modugno (Bari), Italy</p><p>This leaflet was last revised in {MM/YYYY}.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicine Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p><p>Package leaflet: Information for the user</p><p>Pergoveris (300 IU + 150 IU)/0.48 mL solution for injection in pre-filled pen follitropin alfa/lutropin alfa</p><p>Read all of this leaflet carefully before you start using this medicine because it contains important information for you.</p><ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor, pharmacist or nurse.</li><li>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</li><li>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.</li></ul></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpeb7d3517ce728a017d7b2f838a6f78c4"/>
<resource>
<MedicinalProductDefinition>
<id value="mpeb7d3517ce728a017d7b2f838a6f78c4"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpeb7d3517ce728a017d7b2f838a6f78c4"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpeb7d3517ce728a017d7b2f838a6f78c4</b></p><a name="mpeb7d3517ce728a017d7b2f838a6f78c4"> </a><a name="hcmpeb7d3517ce728a017d7b2f838a6f78c4"> </a><a name="mpeb7d3517ce728a017d7b2f838a6f78c4-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/396/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Pergoveris 150 IU/75 IU powder and solvent for solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/396/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Pergoveris 150 IU/75 IU powder and solvent for solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
